We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The Jetstream G3™ Calcium Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01273623
Recruitment Status : Completed
First Posted : January 10, 2011
Results First Posted : May 4, 2015
Last Update Posted : November 18, 2015
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
To investigate the treatment effects with the Jetstream G3 System in moderate to severely calcified peripheral artery disease in the common femoral, superficial femoral or popliteal arteries using intravascular ultrasound (IVUS).

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease Device: Jetstream Atherectomy System Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Single-Arm Study to Evaluate the Effects of the Jetstream G3 System on Calcified Peripheral Vascular Lesions
Study Start Date : January 2011
Actual Primary Completion Date : March 2012
Actual Study Completion Date : March 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Patients with PAD
Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention who have moderate to severe obstructive intraluminal calcium
Device: Jetstream Atherectomy System
to perform atherectomy on calcified lesions

Primary Outcome Measures :
  1. Luminal Area Change [ Time Frame: Day 0 ]
    lumen area change as measured by intravascular ultrasound (IVUS)

Secondary Outcome Measures :
  1. Adjunctive Therapy Use [ Time Frame: Day 0 ]
  2. Residual Diameter Stenosis [ Time Frame: Day 0 ]
    lumen diameter stenosis change post-atherectomy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The patient is ≥ 18 years of age.
  2. Patient has claudication determined to be due to femoropopliteal lesion(s) requiring revascularization.
  3. The target lesion(s) is/are located in the common femoral, superficial femoral or popliteal arteries.
  4. The reference vessel lumen (proximal to target lesion) is ≥ 3.0mm.
  5. The patient is an acceptable candidate for percutaneous intervention using the Jetstream G3 System in accordance with its labeled indications and instructions for use.
  6. The patient has signed approved informed consent.
  7. Moderate or severe vessel obstructive intraluminal calcification as demonstrated by IVUS and angiography.

Exclusion Criteria:

  1. Patient has an uncontrollable allergy to nitinol, stainless steel or other stent materials or to contrast agent.
  2. Patient is unable to take appropriate anti-platelet therapy.
  3. Patient has no distal runoff vessels.
  4. Deep wall calcium.
  5. Interventional treatment is intended for in-stent restenosis at the peripheral vascular site.
  6. Patient has target vessel with moderate or severe angulation (e.g., >30 degrees) or tortuosity at the treatment segment.
  7. Patient has a history of coagulopathy or hypercoagulable bleeding disorder.
  8. Patient is receiving hemodialysis or has impaired renal function (creatinine is > 2.5 mg/dl) at the time of treatment.
  9. Patient has evidence of intracranial or gastrointestinal bleeding within the past 3 months.
  10. Patient has had severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days.
  11. Patient is pregnant or nursing a child.
  12. Intended interventional treatment includes planned laser, brachytherapy or atherectomy procedure other than the Jetstream G3 System.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01273623

Layout table for location information
United States, Arizona
Arizona Heart Institute
Phoenix, Arizona, United States, 85006
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
United States, Michigan
St. John Hopital
Detroit, Michigan, United States, 48236
United States, Tennessee
Mercy Medical Center
Knoxville, Tennessee, United States, 37934
United States, Wisconsin
Wheaton Franciscan Healthcare
Milwaukee, Wisconsin, United States, 53210
Sponsors and Collaborators
Boston Scientific Corporation
Layout table for investigator information
Principal Investigator: Tom Davis, MD St. John Hospital
Principal Investigator: Malcolm Foster Mercy Medical Center
Principal Investigator: Venkatesh Ramaiah, MD Arizona Heart Institute
Principal Investigator: Joseph Ricotta, MD Emory University
Principal Investigator: Thomas Shimshak, MD Wheaton Franciscan Healthcare
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT01273623    
Other Study ID Numbers: D1139
First Posted: January 10, 2011    Key Record Dates
Results First Posted: May 4, 2015
Last Update Posted: November 18, 2015
Last Verified: October 2015
Keywords provided by Boston Scientific Corporation:
PAD, Peripheral Arterial Disease, Calcium, Atherectomy, Jetstream
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases